High Expression of Nicotinamide N-Methyltransferase in Patients with Sporadic Alzheimer’s Disease
Open Access
- 2 January 2021
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 58 (4) , 1769-1781
Abstract
We have previously shown that the expression of nicotinamide N-methyltransferase (NNMT) is significantly increased in the brains of patients who have died of Parkinson’s disease (PD). In this study, we have compared the expression of NNMT in post-mortem medial temporal lobe, hippocampus and cerebellum of 10 Alzheimer’s disease (AD) and 9 non-disease control subjects using a combination of quantitative Western blotting, immunohistochemistry and dual-label confocal microscopy coupled with quantitative analysis of colocalisation. NNMT was detected as a single protein of 29 kDa in both AD and non-disease control brains, which was significantly increased in AD medial temporal lobe compared to non-disease controls (7.5-fold, P < 0.026). There was no significant difference in expression in the cerebellum (P = 0.91). NNMT expression in AD medial temporal lobe and hippocampus was present in cholinergic neurones with no glial localisation. Cell-type expression was identical in both non-disease control and AD tissues. These results are the first to show, in a proof-of-concept study using a small patient cohort, that NNMT protein expression is increased in the AD brain and is present in neurones which degenerate in AD. These results suggest that the elevation of NNMT may be a common feature of many neurodegenerative diseases. Confirmation of this overexpression using a larger AD patient cohort will drive the future development of NNMT-targetting therapeutics which may slow or stop the disease pathogenesis, in contrast to current therapies which solely address AD symptoms.Keywords
This publication has 75 references indexed in Scilit:
- Neuroprotective Effects of NicotinamideN‐Methyltransferase and its Metabolite 1‐MethylnicotinamideJournal of Biochemical and Molecular Toxicology, 2013
- Nicotinamide N-methyltransferase expression in SH-SY5Y neuroblastoma and N27 mesencephalic neurones induces changes in cell morphology via ephrin-B2 and Akt signallingCell Death & Disease, 2013
- Interactions of Pathological Hallmark ProteinsJournal of Biological Chemistry, 2011
- The expression of nicotinamideN-methyltransferase increases ATP synthesis and protects SH-SY5Y neuroblastoma cells against the toxicity of Complex I inhibitorsBiochemical Journal, 2011
- Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteineAtherosclerosis, 2009
- 1‐Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti‐thrombotic activity mediated by a cyclooxygenase‐2/prostacyclin pathwayBritish Journal of Pharmacology, 2007
- A Genomewide Exploration Suggests a New Candidate Gene at Chromosome 11q23 as the Major Determinant of Plasma Homocysteine Levels: Results from the GAIT ProjectThe American Journal of Human Genetics, 2005
- Mitochondria dysfunction of Alzheimer's disease cybrids enhances Aβ toxicityJournal of Neurochemistry, 2004
- Brain Cytochrome Oxidase in Alzheimer's DiseaseJournal of Neurochemistry, 1992
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991